Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood City ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of ...

--Royalty Pharma plc today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan ...

Royalty Pharma Plc. (RPRX) on Tuesday announced a $2 billion funding arrangement with Revolution Medicines (RVMD), aimed at ...

Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology firm focused on targeted treatments for RAS-driven ...

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025. REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc ...

Revolution Medicines expects Phase 3 results for pancreatic cancer in 2026. The royalty agreement includes tiered rates ranging from 0.6% to 7.8% on annual worldwide sales, ...

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to build its own global commercial ...

(RTTNews) - Royalty Pharma plc (RPRX), Tuesday announced a $2 billion funding deal with Revolution Medicines, comprising of a synthetic royalty of upto $1.25 billion on annual worldwide net sales ...

A high-level overview of Revolution Medicines, Inc. WT EXP 121726 (RVMDW) stock. View (RVMDW) real-time stock price, chart, news, analysis, analyst reviews and more.